News » AACC selects Visby Medical as 2022 Disruptive Technology Award Finalist

06/15/2022Press Release

AACC selects Visby Medical as 2022 Disruptive Technology Award Finalist

AACC selects Visby Medical as a finalist for the 2022 Disruptive Technology Award for its handheld point-of-care PCR diagnostic technology.

AACC selects Visby Medical as 2022 Disruptive Technology Award Finalist

SAN JOSE, Calif, – June 15, 2022 – The American Association for Clinical Chemistry (AACC) announced Wednesday that they have selected Visby Medical as a finalist for the 2022 Disruptive Technology Award for its handheld point-of-care PCR diagnostic technology. The Company’s Founder and CEO Adam de la Zerda, Ph.D., will present the technology at the Disruptive Technology Award special session during the 2022 AACC Annual Scientific Meeting on Monday, July 25 in Chicago, Illinois.

“We are excited to present the world’s first instrument-free palm-sized rapid PCR platform to the AACC and illustrate how it is already being adopted by clinicians to transform the infectious disease treatment landscape,” said de la Zerda. “Our vision, to empower anyone to test for any infection anytime in any place, drives our mission to develop innovative technology to disrupt medical diagnostics. Our tests enable accurate results during the patient visit with their clinician, supporting data-informed diagnosis to end the need for presumptive treatment for these infections, the true value of POCT. It is an honor to be recognized.”

The Sexual Health Click Test is a handheld, instrument-free, polymerase chain reaction (PCR) diagnostic that detects Chlamydia, Gonorrhea and Trichomonas via self-collected vaginal swab and returns results in about 30 minutes. It is FDA-cleared and CLIA-waived for point of care use. Because the device is so small, deployable and single-use, the platform has the potential to benefit patients whose clinicians may not have access to high complexity labs.

About Visby Medical™
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedInFacebook, and Twitter.

Media Contact
Doug Hochstedler
press@visby.com

Read more articles & insights

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

12/01/2023Viewpoint

Bracing for Winter Surges: The Imperative of PCR Point-of-Care Testing in Urgent Cares

As the chill in the air intensifies, healthcare systems worldwide brace themselves for a seasonal upswing in respiratory illnesses. This year, the situation is exacerbated by the continuing threat of COVID-19 alongside the potential resurgence of seasonal influenza (Flu A and Flu B).

Read More
Bracing for Winter Surges: The Imperative of PCR Point-of-Care Testing in Urgent Cares

11/18/2023Viewpoint

A Case Study on the Importance of Testing: When SARS-CoV-2 Meets Influenza A

In the setting of a global pandemic, the specter of SARS-CoV-2 infection has understandably dominated the differential diagnosis for respiratory symptoms. However, it is crucial to remember that other respiratory pathogens continue to circulate, potentially leading to varied clinical presentations in patients who share the same exposure or living environment.

Read More
A Case Study on the Importance of Testing: When SARS-CoV-2 Meets Influenza A

05/11/2023Viewpoint

Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected

As we move into the post-public health emergency landscape with the expiration of the national emergency concerning the coronavirus disease 2019 (COVID-19) pandemic on May 11, 2023, it is essential to understand how the healthcare industry has adapted and evolved to address the unique challenges posed by the COVID-19 pandemic.

Read More
Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected